Compare DexCom, Inc. (DXCM) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Norfolk Southern Corporation — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while Norfolk Southern Corporation trades at $317.33 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and Norfolk Southern Corporation pays a 1.7% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Norfolk Southern Corporation for 33 Days on average.
| DXCM | NSC | |
|---|---|---|
Market Cap | $31.86B | $71.20B |
Volume | 3,607,070 | 555,248 |
Sector | Health | Industrials |
52-Week High | $92.34 | $352.98 |
52-Week Low | $54.84 | $278.19 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Norfolk Southern (NSC) trades at $317.14, up 1.26% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $361.86. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Strong profitability is evidenced by a 21.02% net income margin and 16.97% ROE, while news highlights significant institutional investment and progress on the proposed merger with Union Pacific.
The outlook is positive, supported by earnings momentum and potential merger benefits, but risks include integration challenges, fuel cost pressures noted in recent news, and a relatively high P/E ratio of 27.05. The stock offers a dividend yield and growth potential, contingent on successful execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
